Ian Adrian Frani, MD
Infectious Disease · Las Vegas, NVNPI 1003221524
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.4%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Melinta Therapeutics, LLC accounts for 70.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $2,909 and has fallen 61.3% since, to $1,126 in 2025.
Across 36 payments — averaging $128.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$3K
- AbbVie$745
- Astellas Pharma US Inc$230
- Aimmune Therapeutics, Inc.$213
- Viiv Healthcare Company$98
- Shionogi Inc$76
- plus $22 from 1 others
What the payments were for
- Consulting fees$1,72537%
- Speaking & faculty fees$56912%
- Food & beverage$2,09845%
- Education$2305%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 18 | $3,238 |
| AbbVie(2 entities) | 8 | $745 |
| Astellas Pharma US Inc | 4 | $230 |
| Aimmune Therapeutics, Inc. | 3 | $213 |
| Viiv Healthcare Company | 1 | $98 |
| Shionogi Inc | 1 | $76 |
| Merck | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,622 in reported general payments places this provider in the 70th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErtapenemErtapenem Sodium | 25 | $11,056 |
| Daptomycin | 11 | $3,098 |
| CeftriaxoneCeftriaxone Sodium | 11 | $283 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Las Vegas
- Alireza FarabiLas Vegas$588K
- Dhiresh JoshiLas Vegas$96K
- Shaker ItaniLas Vegas$52K
- Dhaval ShahLas Vegas$27K
- Alka RebentishLas Vegas$23K
- Ronald ShockleyLas Vegas$13K
- Chukwudum UcheLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.